ScholarWorks@Korea University College of Medicine: Song, Gwan Gyu

Detailed Information

Song, Gwan Gyu (송관규)

Guro Hospital (Department of Rheumatology, Guro Hospital)

Research Area

Tel 02-2626-3065
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Metaanalysis:107||Polymorphism:87||Rheumatoid arthritis:63||metaanalysis:57||polymorphism:45||rheumatoid arthritis:35||Systemic lupus erythematosus:27||systemic lupus erythematosus:23||Network metaanalysis:17||Osteoarthritis:14||network metaanalysis:13||Efficacy:13||Pathwaybased analysis:12||Ankylosing spondylitis:11||Genomewide association study:11||Safety:10||osteoarthritis:9||Behcet's disease:8||Autoimmune diseases:8||Gout:7||polymorphisms:7||Vitamin D receptor:7||JAK inhibitors:6||Protein tyrosine phosphatase nonreceptor 22:6||Psoriasis:6||Korea:6||Interleukin10:6||scleroderma:6||SLE:6||Lupus nephritis:6||lupus nephritis:6||Tacrolimus:6||vasculitis:6||Angiotensinconverting enzyme:6||CTLA4:5||TNFalpha:5||Vasculitis:5||Inflammation:5||Alzheimer's disease:5||linkage:5||Systemic sclerosis:5||CYC:5||Asthma:5||spondyloarthropathy:5||Cytotoxic T lymphocyte antigen4:5||Tolllike receptor:4||Fibromyalgia:4||Tofacitinib:4||gout:4||Mycophenolate mofetil:4||treatment:4||pathwaybased analysis:4||genome scan:4||Prevalence:4||ankylosing spondylitis:4||disease activity:4||responsiveness:4||MMF:4||Parkinson's disease:4||efficacy:4||p53:4||Genetic polymorphism:3||CCR5Delta 32 polymorphism:3||FAS:3||Arthritis:3||Level:3||Systematic review:3||genomewide association study:3||COMT:3||PPAR gamma:3||Association:3||Periodontitis:3||IL17:3||Diagnostic accuracy:3||Polymorphisms:3||Adalimumab:3||Tumor necrosis factor:3||MTHFR:3||Macrophages:3||Mendelian randomization:3||Mendelian randomization analysis:3||prevalence:3||psoriasis:3||MicroRNA:3||Microarray:3||Biosimilar:3||Interleukin18:3||Mortality:3||Interleukin23R:3||골관절염:3||Bone mineral density:3||Psoriatic arthritis:2||Type 1 diabetes:2||Tumor necrosis factor alpha inducible protein 3:2||osteoporosis:2||MICA:2||Venous thromboembolism:2||Polymorphism, genetic:2||GSTM1:2||ERAP1:2||IL6:2||Vitamin D:2||interleukin6:2||Glucosamine:2||Pulmonary tuberculosis:2||TREM1:2||Lymphoma:2||Wegener granulomatosis:2||SYSTEMICLUPUSERYTHEMATOSUS:2||BMD:2||Chondroitin:2||Dermatomyositis:2||protein tyrosine phosphatase nonreceptor 22:2||만성피로:2||psoriatic arthritis:2||Infliximab:2||adjusted indirect comparison:2||Adiponectin:2||angiotensinconverting enzyme:2||relationship:2||Fas polymorphisms:2||ankylosing:2||rheumatic diseases:2||FCRL3:2||Lung:2||TNFalpha inhibitors:2||Coffee:2||Cogan's syndrome:2||safety:2||RHEUMATOID ARTHRITIS:2||RHEUMATOIDARTHRITIS:2||TNF inhibitors:2||secukinumab:2||RISK:2||Gene expression:2||smoking:2||Gene frequency:2||Pain:2||Olokizumab:2||ADHD:2||PTPN22:2||arthritis:2||Amyotrophic lateral sclerosis:2||Remission:2||autoimmune diseases:2||Genetic association studies:2||susceptibility:2||Response:2||Scleroderma:2||hepatitis B virus reactivation:2||POPULATION:2||FCGR3A:2||systemic sclerosis:2||Rheumatic diseases:2||tacrolimus:2||Rheumatoid:2||giant cell arteritis:2||ADAM33:2||tofacitinib:2||Secukinumab:2||Juvenile idiopathic arthritis:2||bone mineral density:2||Multiple sclerosis:2||Leptin:2||Susceptibility:2||SLC2A9:2||cancer:2||cardiovascular disease:2||ANCA:2||Blood cell count:2||CELLS:2||chronic obstructive pulmonary disease:2||variant:2||AUTOIMMUNEDISEASES:2||Osteoporosis:2||Intraarticular injection:2||CD226:2||coffee:2||vitamin D receptor:2||Cyclophosphamide:2||vitiligo:2||JAK inhibitor:2||SUSCEPTIBILITY LOCI:2||epidemiology:2||Activity:2||Ethnicity:2||AAV:2||Uric acid:2||Cancer:2||mortality:2||Disease susceptibility:2||multiple sclerosis:2||AntiLa/SSB antibody:2||AntiRo/SSA antibody:2||CYTOKINES:2||VEGF:2||INFLAMMATION:2||metaanalysis:2||IgA nephropathy:1||Immune cell quantification:1||Immune deposition:1||Immunoglobulin A (IgA):1||Insulin resistance:1||Interferon regulatory factor 5:1||Interleukin 1:1||Interleukin 18:1||Interleukin1:1||Interleukin12B:1||Interleukin17:1||Interleukin23:1||Interleukin23 R:1||Interleukin23 receptor:1||Interleukin6:1||Interstitial lung disease:1||Intervention:1||Ischemic colitis:1||Ixekizumab:1||JAPANESE:1||JAPANESE POPULATION:1||Janus kinase inhibitors:1||Juvenile arthritis:1||Knee:1||Knee osteoarthritis:1||Korean Health Assessment Questionnaire:1||Llactide):1||Llactidecoglycolide):1||LATVIAN PATIENTS:1||LDSD:1||LOCI:1||LRP5:1||LTalpha:1||Leflunomide:1||Limited:1||Linkage:1||Literature review:1||Low disease activity:1||Lupus erythematosus:1||Lupus erythematosus, systemic:1||Lymphoid tissue inducer:1||MACROPHAGES:1||MAMMALIAN TARGET:1||MCP1:1||MECHANISMS:1||MEDLINE:1||METAANALYSIS:1||MMP:1||MOLECULAR NETWORKS:1||MONOCYTES:1||MPV:1||MTX efficacy:1||MTX toxicity:1||Major depressive disorder:1||Major histocompatibility complex:1||Malignancy:1||Mannosebinding lectin:1||Mannosebinding lectin gene:1||Mast cell:1||Mean platelet volume:1||Membranous lupus nephritis:1||Menopausal hormone therapy:1||Menopause:1||Mesoporous silica:1||Meta analysis:1||Metaanalyse:1||Metaanalysis:1||Metabolic syndrome:1||Methotrexate:1||Metronidazole:1||Migration inhibitory factor:1||Milnacipran:1||Minor salivary gland biopsy:1||Monocyte chemoattractant protein1:1||Monocytes:1||Mortalitat:1||Mucocutaneous lymph node syndrome:1||Myocardial infarction:1||NEPHRITIS:1||NFKB1:1||NITRICOXIDE SYNTHASE:1||NLR:1||NLRP3:1||Naproxen:1||Neuroblastoma:1||Neutrophiltolymphocyte ratio:1||Nintedanib:1||Nocardia asteroides:1||Nocebo effect:1||Nonresponsiveness:1||Nonsteroidal antiinflammatory drugs:1||OSTEOCLASTS:1||Obesity, abdominal:1||Omega3 polyunsaturated fatty acids:1||Open surgical:1||Oral contraceptives:1||Osteoarthrose:1||Osteopontin:1||Osteoprotegerin:1||PAL1:1||PATHWAY:1||PCOS:1||PDCD1:1||PDGFBETARECEPTOR:1||PENTOSIDINE:1||PLR:1||POLYMORPHISM:1||Paget's disease:1||Panax ginseng:1||Paradoxical response:1||Paraffin bath therapy:1||Paraoxonase:1||Pathway analysis:1||Patient reported outcome measures:1||Peripheral tolerance:1||Phox homology domain containing serine/threonine kinase:1||Placebo effect:1||PlaceboControlled Clinical Trial:1||Platelettolymphocyte ratio:1||Poly(D,Llactidecoglycolide):1||Polymorphismus:1||Polymyositis:1||Preeclampsia:1||Pregabalin:1||Primary Sjogren’s syndrome:1||Probiotics:1||Proctitis:1||Productivity loss:1||Progestogen:1||Prognosis:1||Prolactin:1||Prolactin level:1||Promoter regions, genetic:1||Prostaglandin D2 receptor:1||Protein S activity:1||Publication bias:1||Pulmonary:1||Pulmonary embolism:1||Pulmonary sarcoidosis:1||Pyoderma gangrenosum:1||QuantiFERONTB Gold InTube test:1||RA:1||RAPAMYCIN:1||RCT:1||RECEPTORS:1||REGION:1||RESPONSES:1||RPL:1||RZA:1||Rat:1||Recurrent pregnancy loss:1||Relationship:1||Relative efficacy:1||Renal insufficiency, chronic:1||Responsiveness:1||Restenosis:1||Review:1||Risk:1||Rituximab:1||SCLERODERMA:1||SINGLENUCLEOTIDE POLYMORPHISMS:1||SKE:1||SLEDAI:1||SNPS:1||STAT3:1||STAT4:1||STAT4 transcription factor:1||SUPERFAMILY:1||SURVIVAL:1||SYNOVIALFLUID:1||SYNOVIUM:1||SYSTEM:1||Sarcoidosis:1||Sarilumab:1||Schizophrenia:1||Side effects:1||Sjögren’s syndrome:1||Skin Manifestations:1||Sleep time:1||Spondylitis:1||Stat1 protein:1||Stat3 protein:1||Stem cell factor:1||StevenJohnson syndrome:1||StifMeter:1||Stiffness:1||Stigmasterol:1||Strength:1||Stroke:1||Structural efficacy:1||Sugarsweetened beverages:1||Sustained drug delivery:1||Synovial macrophages:1||Systemic lupus:1||TCELLS:1||T1D:1||TANKbinding kinase 1:1||TGFbeta:1||TLR:1||TNF:1||TNF blockers:1||TNFalpha polymorphism:1||TNFalpha308 polymorphism:1||TNFI:1||TNFR:1||TNFR2:1||TOOL:1||TRAF1C5:1||TRANSCRIPTION FACTORS:1||Takayasu arteritis:1||Takayasu's arteritis:1||Tea:1||Telomere:1||Thalidomide:1||Thrombosis:1||Thyroid cancer:1||Tibolone:1||Tocilizumab:1||Tolllike receptor 9:1||Tonsil:1||Toxic epidermal necrolysis:1||Treatment response:1||Trimethoprim/sulfamethoxazole:1||Tumor necrosis factoralpha:1||Tumour necrosis factor alpha:1||Type 2 diabetes:1||Tyrosine kinase 2:1||US:1||Unterernahrung:1||Upadacitinib:1||Uratelowering therapy:1||Urinalysis:1||Urinary TWEAK:1||Uveitis:1||VARIANT:1||VAS:1||VNTR:1||Variant alleles:1||Vascular endothelial growth factor:1||Virusmediated SLE genes:1||Visfatin:1||Vitiligo:1||Voclosporin:1||Xanthophyllomyces dendrorhous:1||YKL40:1||abatacept:1||abdominal aortic aneurysm:1||allopurinol:1||ankylosing spondilitis:1||ankylosis:1||antiCCP antibodies:1||antiinflammatory activity:1||antitumor necrosis factor therapy:1||antitumour necrosis factor therapy:1||antiulcer drug:1||antiphospholipid syndrome:1||aortitis:1||apoptosis:1||arterial thrombosis:1||astaxanthin:1||asthma:1||autoimmune type 1 diabetes mellitus:1||autoimmune uveitis:1||balloon angioplasty:1||baricitinib:1||benzbromarone:1||beta(2)glycoprotein I:1||biologic agent:1||biological agents:1||biologics:1||biosimilars:1||bonchiolitis obliterans:1||brainderived neurotrophic factor:1||breast cancer:1||canakinumab:1||cardiovascular risk:1||carpal bones:1||cervical cancer:1||clinical manifestation:1||cluster analysis:1||coagulation:1||cohort study:1||colchicine:1||complication:1||connective tissue disease:1||coronary artery disease:1||corticosteroid:1||cox:1||creatine kinase:1||criteria:1||crosssectional:1||cryoglobulin:1||cyclophosphamide:1||cytotoxic T lymphocyte antigen4:1||dpeniclla:1||depression:1||dermatomyositis:1||diagnostic accuracy:1||direct oral anticoagulant:1||dmards (synthetic):1||dotinurad:1||dynamic postural control:1||eNOS:1||erythematosus:1||etanercept:1||factor XIII A Val34Leu:1||febuxostat:1||filgotinib:1||flow cytometry:1||fracture:1||gastric antral ulceration:1||gender:1||genetic:1||genetic model:1||genetic polymorphism:1||genetic risk score:1||ginsenoside Rc:1||glioma:1||guselkumab:1||health services research:1||hepatitis B virus occult carrier:1||human:1||hyperuricemia:1||idiopathic arthritis:1||ileocolonoscopic and histologic studies:1||immunoglobulin:1||immunosuppressants:1||inflammation:1||inflammation mediators:1||insulitis:1||interferongamma release assay:1||interferongamma release assays:1||interleukin 17:1||interleukin1:1||interleukin10:1||interleukin12B:1||interleukin23R:1||interleukin4:1||interstitial lung disease:1||intraarticular injection:1||juvenile:1||juvenile idiopathic arthritis:1||kappa light chain:1||latent tuberculosis infection:1||length:1||leptin:1||leptin receptor:1||level:1||lipid's:1||lipoprotein(a):1||low bone mineral density:1||lower trunk muscle:1||lung ultrasound:1||lymphocytes:1||lymphocytic hypophysitis:1||maintenance therapy&nbsp:1||malnutrition:1||matrix metalloproteinase1:1||melanoma:1||metabolic syndrome X:1||methotrexate:1||methoxy poly(ethylene glycol)bpoly(D:1||monocyte chemoattractant protein1:1||monocyte chemoattractant protein1 polymorphisms:1||monocytes/macrophages:1||monotherapy:1||movement time:1||multitarget therapy:1||mycophenolate mofetil:1||myocardial infarction:1||network:1||nocebo:1||organ damage:1||orogastric administration:1||ovarian cancer:1||p38:1||p53 polymorphism:1||pancreatic cancer:1||patientreported outcomes:1||peficitinib:1||pleural effusion:1||poly(D:1||polymyalgia rheumatica:1||preeclampsia:1||prospective study:1||prostaglandinendoperoxide synthase:1||quality of life:1||rebamipide:1||recurrent pregnancy loss:1||relapsing polychondritis:1||restenosis:1||rheumatism:1||rheumatoid:1||risk factors:1||rituximab:1||sarcoidosis:1||schizophrenia:1||sex:1||shared epitope:1||somatic hypermutation:1||spondylarthropathies:1||spondylitis:1||spondyloarthropathies:1||stent implantation:1||steroidsparing effect:1||stomach:1||stress:1||suicide:1||synovial membrane:1||systematic review:1||systemic:1||systemic juvenile:1||systemische Sklerose:1||tacrolimus plus MMF:1||tanezumab:1||tocilizumab:1||tolerability:1||tolllike receptor:1||topiroxostat:1||toxicity:1||tuberculin skin test:1||tuberculin skin tests:1||tumor necrosis factoralpha:1||type 1 diabetes:1||ulcerative colitis:1||uric acid:1||uric acid level:1||validation:1||vascular disease:1||venous thrombosis:1||visual stimuli:1||vitamin D:1||vitamin d receptor:1||voclosporin:1||walking:1||warfarin:1||건강검진:1||대체의학:1||류마티스 관절염:1||류마티즘:1||만성피로증후군:1||유병률:1||유전자 다형성:1||전신성 홍반성 루푸스:1||전신홍반루푸스:1||직장 궤양:1||한국:1||&nbsp:1||허혈성 장염:1||1:1||1,25Dihydroxyviamin D3:1||1,25Dihydroxyvitamin D3:1||15dPGJ(2):1||25(OH)2D3:1||43017:1||5HTTLPR:1||5deoxydelta(12,14)prostaglandin J(2):1||A20:1||ADAM12:1||ADULT ONSET STILL'S DISEASE:1||ALPHA:1||ANALOGS:1||ANCA vasculitis&nbsp:1||ANTIBODIES:1||ARTERY:1||ARTHRITIS:1||AUTOANTIBODY RESPONSE:1||AUTOIMMUNE:1||AZA:1||Acute gout:1||Adipokines:1||Adverse Event:1||Allopurinol:1||Anfalligkeit:1||Angina pectoris:1||Angioedema:1||Anifrolumab:1||AntiCCP antibody:1||AntiTNF:1||Antiinflammation:1||Antiphospholipid syndrome:1||Anticardiolipin Antibody:1||Antiphospholipid antibody syndrome:1||Apolipoprotein E:1||Apoptosis:1||Asporin:1||Associated vasculitis:1||Attentiondeficit/hyperactivity disorder:1||Autism:1||Autoantibodies:1||Autoantigens:1||Autoimmune disease:1||Autoimmunity:1||Autoimmunkrankheiten:1||Azathioprine:1||BCG:1||BD:1||BDNF:1||BONE LOSS:1||Baricitinib:1||Bee venoms:1||Behcet syndrome:1||Behcet 병:1||Belimumab:1||Bioinformatics:1||Biologic agent:1||Biological agent:1||Biological marker:1||Biologics:1||Biomarker:1||Biomarkers:1||Bleomycin:1||Bone density:1||Bone marrow:1||Bosentan:1||Breast cancer:1||CARRD8:1||CCR5:1||CD40:1||COLLAGEN:1||COMPLEMENT:1||COVID19 vaccine:1||COXIBS:1||CT:1||CTLA4 polymorphisms:1||CYP24:1||Calcineurin:1||Candidate gene:1||Celecoxib:1||Chemokine receptor 5 polymorphism:1||Clinical efficacy:1||Complement system proteins:1||Conjunctiva:1||Copy number variation:1||Creatine kinase:1||Crohn's disease:1||Cyclosporin A:1||Cytokines:1||DAS28CRP:1||DAS28ESR:1||DECT:1||DISEASE:1||DISEASES:1||DISH:1||DMARD:1||DMARDs:1||DNA TOPOISOMERASEI:1||Deep vein thrombosis:1||Depression:1||Diabetic nephropathy:1||Diacerein:1||Diagnosis:1||Differentially expressed gene:1||Diffuse:1||Disease Activity Score:1||Disease activity:1||Disease activity score:1||Disease progression:1||Diseasemodifying, antirheumatic drugs:1||Duloxetine:1||ENVIRONMENT:1||ERK1/2:1||ETIOLOGY:1||EVEROLIMUS:1||EXPRESSION:1||Early diagnosis:1||Endometriosis:1||Endothelial nitric oxide synthase:1||Endovascular:1||Estrogen:1||Estrogen receptor:1||Etanercept:1||Ethnic groups:1||Etoricoxib:1||EuroQol EQ5D:1||Extension Study:1||F18 FDG PET:1||F13AI Val34Leu:1||FAMILIES:1||FC gamma RECEPTOR:1||FCG receptor:1||FCGR:1||FCGR polymorphism:1||FCGR2A:1||FCGR3B:1||Fc gamma RECEPTOR:1||Fc gamma receptor:1||Fc receptors:1||Fcgamm receptor:1||Febuxostat:1||Fibrosis:1||Filgotinib:1||GCA:1||GENE:1||GENE POLYMORPHISMS:1||GENES:1||GENETIC POLYMORPHISM:1||GENOMEWIDE ASSOCIATION:1||GLU298ASP:1||GOUT:1||GSTP1:1||GSTT1:1||GSTs:1||GWAS:1||Gene:1||Gene set enrichment analysis:1||Genetic polymorphisms:1||Genetic study:1||Genomewide association studies:1||Genotype:1||Ghrelin:1||Glaucoma:1||Golimumab:1||Gut microbiome:1||HETEROGENEITY:1||HLAB27:1||HLAB27 antigen:1||HLAB51 antigen:1||HLADR:1||HLAG:1||HUMAN OX40 LIGAND:1||Hand:1||Helicobacter pylori:1||Histocompatibility antigens class I:1||Hormone therapy:1||Hypertension:1||ICAM1:1||IDENTIFICATION:1||IFN:1||IL1 beta:1||IL1 receptor antagonist polymorphism:1||IL10:1||IL18:1||IL3:1||IL33:1||IL6 inhibitors:1||IL6 polymorphisms:1||IL6R polymorphism:1||IL37 protein:1||INVIVO:1||INTERLEUKIN 1:1||INTERLEUKIN1:1||IRF5:1||ITGAM:1||IVC thrombosis:1||Ibandronic acid:1||

STATISTICS: Total View :12,650,972; Today View :4,891

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE